Eastman Chemical Company
EMN
$77.53
+6.07%
Eastman Chemical Company is a global specialty chemical company that produces a diverse portfolio of materials, additives, and fibers for a wide range of end markets including transportation, building and construction, and consumables. The company operates as a focused player in the specialty chemicals industry, having strategically divested non-core businesses to concentrate on higher-margin, innovation-driven product offerings. The current investor narrative centers on the company's ability to navigate a challenging demand environment, as evidenced by recent quarterly revenue declines, while its strategic pivot towards advanced materials and circular economy solutions, such as molecular recycling technologies, is a key area of focus for future growth and margin expansion.…
EMN
Eastman Chemical Company
$77.53
Investment Opinion: Should I buy EMN Today?
Rating & Thesis: EMN is rated a Hold. The core thesis is that while the stock appears cheap on a forward earnings basis, significant fundamental headwinds and negative momentum warrant caution, making it unsuitable for new capital until evidence of a turnaround emerges. Analyst sentiment is mixed but leans cautiously optimistic on earnings, though the lack of a clear average price target limits conviction.
Supporting Evidence: The primary valuation support is the forward P/E of 10.5x, which is low and implies a substantial earnings recovery to a consensus $7.95 EPS. The Price/Sales ratio of 0.84x and EV/EBITDA of 9.18x also suggest a non-demanding valuation. The 5.8% FCF yield and 5.2% dividend yield provide a margin of safety. However, these are counterbalanced by a -12.1% YoY revenue decline, a 750 bps gross margin compression, and a stock price that has underperformed the SPY by over 41% in the past year.
Risks & Conditions: The two biggest risks are 1) further margin erosion invalidating the earnings rebound thesis, and 2) a dividend cut if the high payout ratio becomes unsustainable. This Hold rating would upgrade to a Buy if quarterly gross margins stabilize above 20% and revenue declines halt, signaling the downturn has bottomed. It would downgrade to a Sell if the stock breaks below its 52-week low of $56.11 on sustained volume, indicating a failure of the technical support level. Relative to its own history and current fundamentals, the stock is fairly valued to slightly undervalued, but the valuation discount is justified by the elevated operational risks.
Sign up to view all
EMN 12-Month Price Forecast
EMN presents a conflicted picture of deep value versus deteriorating fundamentals. The forward valuation is compelling and suggests the market has priced in substantial bad news, centered on the analyst-anticipated earnings rebound. However, the severity of the recent margin collapse and revenue decline cannot be ignored, and the stock's technical profile reflects deep-seated pessimism. The high dividend yield offers a cushion but is itself a risk due to the elevated payout ratio. The stance is neutral due to the high uncertainty around the timing and magnitude of a potential turnaround. Confidence is medium, as the data clearly outlines both the opportunity and the peril. The stance would turn bullish on evidence of sequential margin improvement and revenue stabilization; it would turn bearish on a break below the $56 support level or a dividend cut announcement.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eastman Chemical Company's 12-month outlook, with a consensus price target around $100.79 and implied upside of +30.0% versus the current price.
Average Target
$100.79
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$62 - $101
Analyst target range
The stock is covered by 8 analysts, and the institutional ratings show a mix of Buy, Hold, and Overweight recommendations, with recent actions including a downgrade from RBC Capital from 'Outperform' to 'Sector Perform' in January 2026. The consensus sentiment leans cautiously optimistic, though the average target price is not explicitly provided in the data; analyst estimates point to an average EPS of $7.95 and average revenue of $9.57 billion for the coming year, but without a specific price target, the implied upside cannot be calculated from the given dataset. The target range can be inferred from the EPS estimates, with a low of $7.72 and a high of $8.60, representing a relatively tight spread of about 11%, which suggests a fair degree of consensus on near-term earnings potential, though the lack of explicit price targets limits the analysis of valuation expectations and potential stock price catalysts.
Bulls vs Bears: EMN Investment Factors
The investment debate for EMN centers on a classic value versus value trap scenario. The bull case is built on a deeply discounted forward P/E of 10.5x, strong free cash flow supporting a high yield, and clear analyst consensus for a significant earnings recovery to $7.95 EPS. The bear case highlights severe fundamental deterioration, with a 12% revenue decline and a 750 basis point gross margin compression year-over-year, reflected in persistent technical weakness and elevated short interest. Currently, the bearish evidence from deteriorating fundamentals and negative momentum appears stronger, but the valuation discount is substantial. The single most important tension is whether the company's strategic pivot and cost actions can successfully stabilize margins and drive the anticipated earnings rebound before the dividend or balance sheet comes under pressure.
Bullish
- Deeply Discounted Forward Valuation: The forward P/E of 10.5x is significantly below the trailing P/E of 15.5x, reflecting market expectations for a substantial earnings recovery. This valuation is also at the lower end of its own historical range, suggesting the stock is pricing in significant pessimism.
- Strong Free Cash Flow Generation: The company generated $424M in TTM free cash flow, yielding 5.8% based on market cap. This robust cash flow supports the 5.2% dividend yield and provides financial flexibility for strategic investments, even amidst revenue headwinds.
- Analyst Consensus on Earnings Recovery: Analysts project average forward EPS of $7.95, representing a massive recovery from recent depressed quarterly results. The tight 11% spread between low ($7.72) and high ($8.60) estimates indicates a high degree of confidence in this earnings rebound.
- Strategic Focus on Higher-Margin Segments: The company has divested non-core businesses to focus on advanced materials and circular economy solutions like molecular recycling. This strategic pivot is aimed at improving long-term margins, though current gross margin of 17.1% shows near-term pressure.
Bearish
- Severe Revenue and Margin Contraction: Q4 2025 revenue declined 12.1% YoY, while gross margin collapsed to 17.1% from 24.7% a year prior. This sequential deterioration from Q1 2025's 24.8% gross margin indicates persistent demand and pricing headwinds across its portfolio.
- Persistent Technical Downtrend: The stock has underperformed the SPY by over 41% in the past year, trading near 61% of its 52-week range. With a beta of 1.17, it exhibits higher volatility than the market while delivering significantly negative returns, indicating weak investor sentiment.
- Elevated Short Interest and Analyst Downgrade: A short interest ratio of 2.9 days suggests significant bearish positioning. This skepticism is echoed by RBC Capital's January 2026 downgrade from 'Outperform' to 'Sector Perform', reflecting concerns about the near-term outlook.
- High Dividend Payout Ratio: The dividend payout ratio stands at 80.4%, which is elevated and could pressure financial flexibility if earnings do not recover as anticipated. While the 5.2% yield is attractive, its sustainability depends on the projected EPS rebound materializing.
EMN Technical Analysis
The stock is in a pronounced downtrend over the past year, with a 1-year price change of -10.91%, significantly underperforming the broader market's 30.59% gain. Currently trading at $72.00, the price sits at approximately 61% of its 52-week range ($56.11 to $84.18), indicating it is much closer to its annual lows than its highs, which may present a value opportunity but also reflects persistent negative momentum and weak relative strength. Recent momentum shows a modest short-term recovery attempt, with a 3-month price change of +4.79% and a 1-month change of +0.84%, though these pale in comparison to the SPY's respective gains of +3.59% and +8.70%, resulting in negative relative strength figures of +1.20 and -7.86 over those periods, signaling the stock is failing to keep pace with the market's advance. Key technical support is clearly defined at the 52-week low of $56.11, while resistance looms at the 52-week high of $84.18; a sustained break below support would signal a continuation of the bearish trend, whereas a move above the recent trading range towards resistance would require a significant fundamental catalyst. The stock's beta of 1.174 indicates it is approximately 17% more volatile than the SPY, which is important for risk-adjusted positioning given its current weak trend and elevated short interest ratio of 2.9.
Beta
—
—
Max Drawdown
-36.6%
Largest decline past year
52-Week Range
$56-$84
Price range past year
Annual Return
+1.7%
Cumulative gain past year
| Period | EMN Return | S&P 500 |
|---|---|---|
| 1m | +2.3% | +10.0% |
| 3m | +11.8% | +4.1% |
| 6m | +30.3% | +5.7% |
| 1y | +1.7% | +29.0% |
| ytd | +20.5% | +5.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EMN Fundamental Analysis
Revenue growth has turned negative, with Q4 2025 revenue of $1.97 billion representing a -12.1% year-over-year decline, continuing a decelerating trend from stronger prior-year quarters; segment data shows the top line is broadly distributed across Additives & Functional Products ($662M), Advanced Materials ($656M), Chemical Intermediates ($418M), and Fibers ($234M), but the overall trajectory implies demand headwinds across its portfolio. Profitability remains under pressure, with Q4 2025 net income of $105 million and a gross margin of 17.1%, a significant compression from the 24.7% gross margin reported in Q4 2024; the trailing twelve-month net margin stands at 5.4%, and while the company is profitable, the sequential decline in margins from earlier quarters in 2025 highlights ongoing cost and pricing challenges. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.85, and liquidity is adequate with a current ratio of 1.37; critically, the company generated $424 million in trailing twelve-month free cash flow, providing a FCF yield of approximately 5.8% based on its market cap, which supports its dividend (payout ratio of 80.4%) and offers some financial flexibility for internal investments despite the operating headwinds.
Quarterly Revenue
$2.0B
2025-12
Revenue YoY Growth
-0.12%
YoY Comparison
Gross Margin
+0.17%
Latest Quarter
Free Cash Flow
$424000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EMN Overvalued?
Given a positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 15.45x, while the forward P/E is notably lower at 10.52x, indicating the market expects a significant recovery in earnings, with consensus EPS estimates for the coming year at $7.95. Compared to industry averages, the stock trades at a discount on a Price/Sales basis, with a PS ratio of 0.84x, though direct industry average comparisons are not provided in the data; the EV/EBITDA of 9.18x and EV/Sales of 1.46x suggest a market valuation that is not demanding relative to its cash flow and sales. Historically, the current trailing P/E of 15.45x is below the stock's own historical range seen in recent quarters, which has included multiples above 38x during periods of depressed earnings (Q3 2025) and as low as 8.07x (Q4 2024), positioning the current valuation in the lower-middle band of its recent history, which may reflect a balance between discounted earnings and ongoing fundamental concerns.
PE
15.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -27x~2433x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: EMN faces significant financial risks from its deteriorating profitability. The gross margin compression from 24.7% to 17.1% year-over-year in Q4 2025 is severe and, if sustained, threatens the company's ability to cover its dividend, which currently consumes 80.4% of earnings. Revenue concentration is less of an issue due to a diversified segment portfolio, but the broad-based -12.1% YoY revenue decline indicates systemic demand weakness. The primary risk is that the projected earnings recovery fails to materialize, leaving the stock's valuation unjustified and potentially forcing a dividend cut, which would be a major negative catalyst given the income-oriented shareholder base.
Market & Competitive Risks: The stock's valuation, while low, carries compression risk if the earnings rebound is delayed. Trading at a forward P/E of 10.5x, it is not demanding, but further multiple contraction is possible if the sector faces a downturn or if the company's strategic initiatives in advanced materials fail to gain traction against larger, better-capitalized competitors. The stock's beta of 1.174 indicates it is 17% more volatile than the market, amplifying downside during broad sell-offs. The recent analyst downgrade highlights growing skepticism about the near-term turnaround narrative, which could lead to further de-rating if other analysts follow suit.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current downtrend, where demand remains weak, cost pressures persist, and the anticipated EPS recovery fails. This could trigger a dividend reduction, leading to a sell-off from income investors. Combined with a loss of confidence in the turnaround story, the stock could re-test its 52-week low of $56.11. From the current price of $72, this represents a potential downside of approximately -22%. A breach of this level could see the stock fall further, potentially towards the $50 range, as the market prices in a prolonged earnings depression and balance sheet concerns.
FAQ
The key risks are, in order of severity: 1) Operational Risk: Continued gross margin pressure, as seen in the 750 bps year-over-year collapse to 17.1%, which threatens profitability and the earnings recovery thesis. 2) Dividend Sustainability Risk: The high payout ratio of 80.4% could force a dividend cut if EPS does not recover as forecasted, triggering a sell-off. 3) Market Risk: The stock's beta of 1.174 makes it more volatile than the market, and its -41% relative strength vs. the SPY indicates persistent negative momentum. 4) Demand Risk: Broad-based revenue declines across segments suggest exposure to a weakening global industrial economy.
The 12-month forecast for EMN is a range-bound outlook with a skewed risk/reward. The base case (55% probability) sees the stock trading between $72 and $80 as it achieves consensus EPS of $7.95 but struggles with multiple expansion. The bull case (25% probability) targets $84 to $90 on successful margin recovery and P/E expansion. The bear case (20% probability) risks a fall to the $56 to $65 range if fundamentals worsen. The most likely scenario is the base case, predicated on the critical assumption that the company can stabilize its margins and halt the revenue decline, allowing the forward earnings estimate to be met.
EMN appears fairly valued to slightly undervalued based on forward earnings, but the discount is justified by its risks. The forward P/E of 10.5x is low and implies the market expects a strong earnings rebound. The Price/Sales ratio of 0.84x and EV/EBITDA of 9.18x are also not demanding. However, compared to its own history, the current trailing P/E of 15.5x sits in the lower-middle range, reflecting the market's skepticism. The valuation is not overvalued; it is a discount that accurately prices in the current operational challenges and uncertainty surrounding the turnaround. The market is paying a fair price for a company in transition.
EMN is a speculative buy only for investors with a high risk tolerance and a long-term horizon. The forward P/E of 10.5x and dividend yield of 5.2% are attractive, offering a significant margin of safety if the projected earnings recovery to $7.95 EPS materializes. However, the severe -12.1% revenue decline and collapsing gross margins present substantial fundamental risk. It could be a good buy for contrarian value investors seeking high yield, but it is not suitable for conservative investors or those seeking stable growth, as the downside risk to the 52-week low of $56.11 (-22%) is real if the turnaround stalls.
EMN is unsuitable for short-term trading due to its high volatility (beta 1.17), negative momentum, and dependence on uncertain quarterly fundamentals. It is primarily a long-term, contrarian investment for investors willing to hold for 3-5 years to see through its strategic transition and potential cyclical recovery. The high dividend yield supports a total return approach for income investors with patience. A minimum holding period of 18-24 months is suggested to allow for the execution of the company's turnaround plan and for the earnings recovery narrative to play out, navigating likely volatility along the way.
